2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy
Gilead Highlights Oncology Ambitions In Q4
Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.
You may also be interested in...
The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.
The COVID-19 windfall meant a 12% rise in spending on medicines in the US in 2021 versus 2020, but just 5% excluding COVID, which is expected to fall to 1%-4% compound annual growth through 2026.
Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.